Latest Content

Henlius and Sandoz ink a biosimilars collaboration, ADVI's Tyler Seville makes the case for 340B reform, and RELEX's Rohit Tripathi weighs in on what real pharma reshoring requires.

Henlius Biotech has granted Sandoz exclusive ex-China commercialization rights to up to 10 monoclonal antibody and ADC biosimilars for up to $322 million.

Rohit Tripathi, VP of Industry Strategy at RELEX, discusses how pharmaceutical reshoring demands end-to-end capability not just domestic final assembly.

ADVI’s associate director of market access policy strategy discusses how 340B grew to $100 billion, lost its safety-net purpose, and became a compliance nightmare when the IRA arrived.

From a $1.32 billion rare epilepsy acquisition to AI drug discovery partnerships, biotech IPOs, and a rare disease investment rebound — here's what moved the market this week.

Pharmaceutical Executive releases its 2026 Top 50 company rankings, FDA grants Bristol Myers Squibb's Zenbexus accelerated approval for multiple myeloma, and PwC's Glenn Hunzinger talks the shifting economics of pharma dealmaking.

MedAdvisor Solutions has rebranded as Adheris, restoring a name that has been a fixture in patient engagement for more than three decades.

A changing of the guard atop Pharm Exec’s latest listing of the top biopharma Rx revenue producers reflects an industry being remade in real time, becoming as much a map of franchise quality and market momentum as it is the strategic shifts and bets necessary to turn today’s disruption into tomorrow’s growth.

As trust shifts from a stated value to an operating condition, pharmaceutical leaders face new expectations for how credibility is built, governed and sustained under continuous scrutiny.

FDA has granted accelerated approval to Zenbexus plus daratumumab and Hyaluronidase-fihj and dexamethasone for multiple myeloma after at least one prior line of therapy.

ADVI's Tyler Seville on how the IRA's drug pricing provisions are creating compliance burdens manufacturers can't meet without data they don't have.

A funding roundup covers new IPO and Series A raises across Silence Therapeutics, AbCellera, Beyang Therapeutics, and Remepy, Tyler Seville of ADVI examines the policy concerns building around the 340B Drug Pricing Program, and Pharmaceutical Executive names its 2026 Emerging Pharma Leaders.

From guiding pursuits in artificial intelligence and R&D to scientific marketing and company building, meet Pharm Exec’s new slate of select rising leaders who are helping to shape the next generation of biopharma innovation.